BACKGROUND/AIM: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). PATIENTS AND METHODS: In a cohort of 206 patients with MPN, MPs' procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples. RESULTS: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2V617F mutation, history of thrombosis, platelets >400×109/l, hematocrit >45%, or leukocytes >10×109/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. CONCLUSION: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.

Department of Clinical Hematology University Hospital Brno Brno Czech Republic

Department of Clinical Hematology University Hospital Brno Brno Czech Republic;

Faculty of Medicine Masaryk University Brno Czech Republic

Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Barteneva NS, Fasler-Kan E, Bernimoulin M, Stern JN, Ponomarev ED, Duckett L, Vorobjev IA. Circulating microparticles: square the circle. BMC Cell Biol. 2013;14:23. doi: 10.1186/1471-2121-14-23. PubMed DOI PMC

Nomura S, Shimizu M. Clinical significance of procoagulant microparticles. J Intensive Care. 2015;3(1):2. doi: 10.1186/s40560-014-0066-z. PubMed DOI PMC

Lacroix R, Dubois C, Leroyer AS, Sabatier F, Dignat-George F. Revisited role of microparticles in arterial and venous thrombosis. J Thromb Haemost. 2013;11 Suppl 1:24–35. doi: 10.1111/jth.12268. PubMed DOI

Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A, Terpstra WE, Falanga A. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica. 2009;94(7):911–918. doi: 10.3324/haematol.13774. PubMed DOI PMC

Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res. 2010;126(3):238–242. doi: 10.1016/j.thromres.2010.06.025. PubMed DOI

Kissova J, Ovesna P, Bulikova A, Zavřelova J, Penka M. Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience. Blood Coagul Fibrinolysis. 2015;26(4):448–453. doi: 10.1097/MBC.0000000000000293. PubMed DOI

Marchetti M, Tartari CJ, Russo L, Panova-Noeva M, Leuzzi A, Rambaldi A, Finazzi G, Woodhams B, Falanga A. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol. 2014;89(1):68–73. doi: 10.1002/ajh.23590. PubMed DOI PMC

Zhang W, Qi J, Zhao S, Shen W, Dai L, Han W, Huang M, Wang Z, Ruan C, Wu D, Han Y. Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms. Oncol Lett. 2017;14(2):2531–2536. doi: 10.3892/ol.2017.6459. PubMed DOI PMC

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544. PubMed DOI

Stein B, Patel K, Scherber R, Yu J, Paranagama D, Miller C. Mortality and causes of death of patients with polycythemia vera: Analysis of the reveal prospective, observational study. Blood. 2021;136(Supplement 1):36–37. doi: 10.1182/blood-2020-137144. DOI

Lekovic D, Gotic M, Sefer D, Mitrovic-Ajtic O, Cokic V, Milic N. Predictors of survival and cause of death in patients with essential thrombocythemia. Eur J Haematol. 2015;95(5):461–466. doi: 10.1111/ejh.12517. PubMed DOI

Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G, Barosi G. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–782. doi: 10.1182/blood-2009-08-238956. PubMed DOI

Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep. 2017;12(5):389–396. doi: 10.1007/s11899-017-0400-3. PubMed DOI

Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, Serizawa K, Rai S, Morita Y, Hanamoto H, Tsubaki K, Nishio K, Matsumura I. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. Int J Hematol. 2017;106(5):691–703. doi: 10.1007/s12185-017-2302-5. PubMed DOI

Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(3):348–358. doi: 10.1055/s-0034-1370794. PubMed DOI

Mooberry MJ, Key NS. Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry A. 2016;89(2):111–122. doi: 10.1002/cyto.a.22647. PubMed DOI PMC

Voukalis C, Shantsila E, Lip GYH. Microparticles and cardiovascular diseases. Ann Med. 2019;51(3-4):193–223. doi: 10.1080/07853890.2019.1609076. PubMed DOI PMC

García-Santos G, Serrano Pertierra E, Fernández Hevia M, Duque Alcorta JM, Sánchez Domínguez L, Blanco López MC, García Flórez LJ. Potential of extracellular microvesicles as new colorectal cancer biomarker. Br J Surg. 2021;108:znab160.075. doi: 10.1093/bjs/znab160.075. DOI

Charpentier A, Lebreton A, Rauch A, Bauters A, Trillot N, Nibourel O, Tintillier V, Wemeau M, Demory JL, Preudhomme C, Jude B, Lecompte T, Cambier N, Susen S. Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia. Haematologica. 2016;101(9):e365–e368. doi: 10.3324/haematol.2016.144279. PubMed DOI PMC

Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R, European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446–2452. doi: 10.1182/blood-2006-08-042515. PubMed DOI

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857–5859. doi: 10.1182/blood-2011-02-339002. PubMed DOI

Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013;54(9):1989–1995. doi: 10.3109/10428194.2012.759656. PubMed DOI

Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017;7(12):662. doi: 10.1038/s41408-017-0035-6. PubMed DOI PMC

Seguro FS, Teixeira LLC, da Rosa LI, da Silva WF, Nardinelli L, Bendit I, Rocha V. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms. J Thromb Thrombolysis. 2020;49(4):667–672. doi: 10.1007/s11239-019-02029-y. PubMed DOI

Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33(1):67–73. doi: 10.1016/j.leukres.2008.06.006. PubMed DOI

Barbui T, Falanga A. Molecular biomarkers of thrombosis in myeloproliferative neoplasms. Thromb Res. 2016;140 Suppl 1:S71–S75. doi: 10.1016/S0049-3848(16)30102-5. PubMed DOI

Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, Mazharian A, Guerrero JA, Li J, Soranzo N, Green AR, Watson SP, Ghevaert C. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood. 2013;122(23):3787–3797. doi: 10.1182/blood-2013-06-501452. PubMed DOI PMC

Panova-Noeva M, Marchetti M, Spronk HM, Russo L, Diani E, Finazzi G, Salmoiraghi S, Rambaldi A, Barbui T, Ten Cate H, Falanga A. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol. 2011;86(4):337–342. doi: 10.1002/ajh.21974. PubMed DOI

Matsuura S, Thompson CR, Belghasem ME, Bekendam RH, Piasecki A, Leiva O, Ray A, Italiano J, Yang M, Merill-Skoloff G, Chitalia VC, Flaumenhaft R, Ravid K. Platelet dysfunction and thrombosis in JAK2V617F-mutated primary myelofibrotic mice. Arterioscler Thromb Vasc Biol. 2020;40(10):e262–e272. doi: 10.1161/ATVBAHA.120.314760. PubMed DOI PMC

Alvarez-Larrán A, Arellano-Rodrigo E, Reverter JC, Domingo A, Villamor N, Colomer D, Cervantes F. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol. 2008;87(4):269–276. doi: 10.1007/s00277-007-0386-3. PubMed DOI

Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008;112(10):4061–4068. doi: 10.1182/blood-2008-06-164087. PubMed DOI

Kim HJ, Choi EH, Lim YJ, Kil HR. The usefulness of platelet-derived microparticle as biomarker of antiplatelet therapy in Kawasaki disease. J Korean Med Sci. 2017;32(7):1147–1153. doi: 10.3346/jkms.2017.32.7.1147. PubMed DOI PMC

Skeppholm M, Mobarrez F, Malmqvist K, Wallén H. Platelet-derived microparticles during and after acute coronary syndrome. Thromb Haemost. 2012;107(6):1122–1129. doi: 10.1160/TH11-11-0779. PubMed DOI

Duarte RC, Gonçalves LH, Campos FM, Filho OA, Alves MT, Fernandes AP, Borges KB, Dusse LM, Faria MC, Gonçalves GS, Bosco AA, Sandrim VC, Carvalho MG. Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus. Blood Coagul Fibrinolysis. 2015;26(2):123–130. doi: 10.1097/MBC.0000000000000199. PubMed DOI

Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–4781. doi: 10.1182/blood-2013-01-478891. PubMed DOI PMC

Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, Angona A, Gómez M, Muiña B, Guillén H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363–1369. doi: 10.1182/blood-2011-10-387787. PubMed DOI

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T, CYTO-PV Collaborative Group Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33. doi: 10.1056/NEJMoa1208500. PubMed DOI

Enblom-Larsson A, Girodon F, Bak M, Hersby D, Jooste V, Hasselbalch H, Johansson P, Andreasson B. A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera. Br J Haematol. 2017;177(5):800–805. doi: 10.1111/bjh.14625. PubMed DOI

Gordeuk VR, Key NS, Prchal JT. Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. Haematologica. 2019;104(4):653–658. doi: 10.3324/haematol.2018.210732. PubMed DOI PMC

Klatt C, Krüger I, Zey S, Krott KJ, Spelleken M, Gowert NS, Oberhuber A, Pfaff L, Lückstädt W, Jurk K, Schaller M, Al-Hasani H, Schrader J, Massberg S, Stark K, Schelzig H, Kelm M, Elvers M. Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis. J Clin Invest. 2018;128(9):3906–3925. doi: 10.1172/JCI92077. PubMed DOI PMC

Falanga A, Marchetti M, Schieppati F. Prevention and management of thrombosis in BCR/ABL-negative myeloproliferative neoplasms. Hamostaseologie. 2021;41(1):48–57. doi: 10.1055/a-1334-3259. PubMed DOI

Takaishi K, Takeuchi M, Tsukamoto S, Takayama N, Oshima M, Kimura K, Isshiki Y, Kayamori K, Hino Y, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Ohwada C, Iseki T, Nakamura S, Eto K, Iwama A, Yokote K, Nakaseko C, Sakaida E. Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells. Haematologica. 2020;105(5):e216–e220. doi: 10.3324/haematol.2018.214841. PubMed DOI PMC

Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, Vianelli N, Luigia Randi M, Bertozzi I, De Stefano V, Za T, Rossi E, Ruggeri M, Elli E, Cacciola R, Cacciola E, Pogliani E, Rodeghiero F, Baccarani M, Passamonti F, Finazzi G, Rambaldi A, Bosi A, Cazzola M, Barbui T, Vannucchi AM, AGIMM Investigators Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol. 2012;87(5):552–554. doi: 10.1002/ajh.23160. PubMed DOI